Elvitegravir Reduces Monocyte Activation and Vascular Inflammation More Than Efavirenz
Background: Heightened inflammation and monocyte activation may drive cardiovascular disease and other comorbidities in HIV. Little is known about the differential effects of antiretrovirals on immune activation. Methods: A randomized, double blind trial in ART-naïve HIV-infected adults comparing safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir (EVG/C/F/TDF) and efavirenz/emtricitabine/tenofovir (EFV/F/TDF) was previously performed. From a random sample of…